Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2010
Business Overview: NanoViricides is a development-stage biopharmaceutical company focused on discovering, developing, and commercializing nanomedicine therapeutics for viral diseases. The company utilizes proprietary "nanoviricide" technology, which employs self-assembling polymeric micelles to target and destroy virus particles. The company has no commercial products and has not generated any revenue to date.
Key Financial Metrics
| Metric | Year Ended June 30, 2010 | Year Ended June 30, 2009 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,744,208) | $(2,787,798) |
| Accumulated Deficit | $(16,739,743) | $(11,995,535) |
| Cash and Cash Equivalents | $6,955,733 | $1,689,442 |
| Total Assets | $8,992,358 | $3,001,261 |
| Total Liabilities | $2,473,654 | $515,719 |
| Research & Development Expenses | $3,367,409 | $1,791,934 |
| General & Administrative Expenses | $1,735,066 | $1,085,920 |
Note: The filing does not provide specific data for operating margins or debt ratios as the company has no revenue and no long-term debt.
Material Changes vs. Prior Period
- Financing Activity: The company significantly improved its liquidity position. In September 2009, it raised approximately $3.2 million. In May 2010, it raised $5.0 million through a registered shelf offering (Series B Convertible Preferred Stock) from a single investor, Seaside 88, LP. A subsequent $2.5 million drawdown occurred in September 2010 (post-period).
- Expense Growth: Net loss increased by approximately 70% year-over-year, driven primarily by a 88% increase in R&D expenses ($1.58 million increase) and a 60% increase in G&A expenses ($649,000 increase). The G&A increase was largely due to the recognition of fair value compensation paid in stock.
- Asset Base: Total assets nearly tripled from $3.0 million to $9.0 million, primarily due to the influx of cash from financing activities.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Cash Runway: Management estimates that current cash reserves ($6.96 million) combined with subsequent financing ($2.5 million) are sufficient to fund operations for approximately 18 months (through December 31, 2011).
- Capital Requirements: The company projects a need for an additional $10 million to $15 million over the next 18-24 months to fund toxicology studies, material characterization, and the filing of an Investigational New Drug (IND) application with the FDA.
- Development Milestones: The company aims to file a pre-IND application in the first half of 2011 for its lead candidates (FluCide, HIVCide, or Eye Drops).
Management Commentary:
- The company has consolidated its influenza programs into a single "FluCide" candidate effective against all influenza A viruses.
- Significant pre-clinical efficacy was reported for candidates against HIV (superior to HAART in animal models), Dengue (50% survival in lethal models), and Herpes (99.99% reduction in viral load).
Risks and Contingencies:
- Going Concern: The company is a development-stage entity with no revenue and a history of losses. Continued operations depend on raising additional capital.
- Regulatory Risk: All products are in pre-clinical stages. There is no assurance that pre-clinical results will translate to human efficacy or that FDA approval will be obtained.
- Related Party Dependence: The company relies exclusively on TheraCour Pharma, Inc. (a related party owned by the President) for the manufacturing of core nanomaterials and holds an exclusive license from them. TheraCour owns approximately 24.9% of the company's common stock.
- Intellectual Property: The company relies on licensed patents and pending applications; there is no assurance these will be issued or enforceable.
Key Facts for Investor Verification
- Revenue Status: Verify that the company has generated zero revenue to date and has no commercial products.
- Liquidity Runway: Confirm the 18-month cash runway estimate and the specific terms of the $10M-$15M capital raise required to reach the IND filing stage.
- Related Party Transactions: Review the exclusive license agreement with TheraCour Pharma, Inc., including the 15% royalty on future net sales and the development fee structure (costs plus 30%).
- Pre-Clinical Data: Scrutinize the pre-clinical efficacy claims (e.g., HIVCide superiority to HAART, Dengue survival rates) as these are preliminary and not yet validated in human trials.
- Stock Dilution: Note the issuance of Series B Convertible Preferred Stock and the potential for significant dilution upon conversion to common stock.